Logo image of PROK

PROKIDNEY CORP (PROK) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PROK - US74291D1046 - Common Stock

2.14 USD
-0.15 (-6.55%)
Last: 1/20/2026, 8:11:20 PM
2.14 USD
0 (0%)
After Hours: 1/20/2026, 8:11:20 PM
Fundamental Rating

1

PROK gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. PROK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PROK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year PROK has reported negative net income.
  • PROK had a negative operating cash flow in the past year.
  • In the past 5 years PROK always reported negative net income.
  • In the past 5 years PROK always reported negative operating cash flow.
PROK Yearly Net Income VS EBIT VS OCF VS FCFPROK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -20.20%, PROK is in the better half of the industry, outperforming 76.19% of the companies in the same industry.
Industry RankSector Rank
ROA -20.2%
ROE N/A
ROIC N/A
ROA(3y)-14.39%
ROA(5y)-68.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PROK Yearly ROA, ROE, ROICPROK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PROK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PROK Yearly Profit, Operating, Gross MarginsPROK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

4

2. Health

2.1 Basic Checks

  • PROK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PROK has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, PROK has an improved debt to assets ratio.
PROK Yearly Shares OutstandingPROK Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
PROK Yearly Total Debt VS Total AssetsPROK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • PROK has an Altman-Z score of -5.38. This is a bad value and indicates that PROK is not financially healthy and even has some risk of bankruptcy.
  • PROK has a Altman-Z score of -5.38. This is in the lower half of the industry: PROK underperforms 61.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.38
ROIC/WACCN/A
WACC8.88%
PROK Yearly LT Debt VS Equity VS FCFPROK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M -1B

2.3 Liquidity

  • PROK has a Current Ratio of 10.32. This indicates that PROK is financially healthy and has no problem in meeting its short term obligations.
  • PROK's Current ratio of 10.32 is amongst the best of the industry. PROK outperforms 82.10% of its industry peers.
  • PROK has a Quick Ratio of 10.32. This indicates that PROK is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 10.32, PROK belongs to the best of the industry, outperforming 82.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.32
Quick Ratio 10.32
PROK Yearly Current Assets VS Current LiabilitesPROK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

  • PROK shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • PROK is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.95% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.22%
EPS Next 2Y11.66%
EPS Next 3Y8.13%
EPS Next 5Y7.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PROK Yearly Revenue VS EstimatesPROK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
PROK Yearly EPS VS EstimatesPROK Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • PROK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PROK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PROK Price Earnings VS Forward Price EarningsPROK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PROK Per share dataPROK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.66%
EPS Next 3Y8.13%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for PROK!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PROKIDNEY CORP

NASDAQ:PROK (1/20/2026, 8:11:20 PM)

After market: 2.14 0 (0%)

2.14

-0.15 (-6.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-13
Inst Owners28.53%
Inst Owner Change0.17%
Ins Owners1.83%
Ins Owner Change0%
Market Cap643.78M
Revenue(TTM)744.00K
Net Income(TTM)-71.03M
Analysts78.67
Price Target6.85 (220.09%)
Short Float %14.37%
Short Ratio11.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.18%
Min EPS beat(2)10.87%
Max EPS beat(2)11.49%
EPS beat(4)3
Avg EPS beat(4)7.3%
Min EPS beat(4)-12.23%
Max EPS beat(4)19.08%
EPS beat(8)7
Avg EPS beat(8)13.03%
EPS beat(12)10
Avg EPS beat(12)22.79%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.1%
PT rev (3m)15.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.33%
EPS NY rev (1m)0%
EPS NY rev (3m)8.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)100.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 865.29
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0
BVpS-3.35
TBVpS-3.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.39%
ROA(5y)-68.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 553.76%
Cap/Sales 4697.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.32
Quick Ratio 10.32
Altman-Z -5.38
F-Score2
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)497.21%
Cap/Depr(5y)464.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y23.22%
EPS Next 2Y11.66%
EPS Next 3Y8.13%
EPS Next 5Y7.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.36%
EBIT Next 3Y0.42%
EBIT Next 5YN/A
FCF growth 1Y-29.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.94%
OCF growth 3YN/A
OCF growth 5YN/A

PROKIDNEY CORP / PROK FAQ

What is the ChartMill fundamental rating of PROKIDNEY CORP (PROK) stock?

ChartMill assigns a fundamental rating of 1 / 10 to PROK.


What is the valuation status of PROKIDNEY CORP (PROK) stock?

ChartMill assigns a valuation rating of 0 / 10 to PROKIDNEY CORP (PROK). This can be considered as Overvalued.


What is the profitability of PROK stock?

PROKIDNEY CORP (PROK) has a profitability rating of 1 / 10.


What is the expected EPS growth for PROKIDNEY CORP (PROK) stock?

The Earnings per Share (EPS) of PROKIDNEY CORP (PROK) is expected to grow by 23.22% in the next year.